Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Biol Pharm Bull ; 40(6): 922-925, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28566635

RESUMEN

Ritodrine, a drug for the treatment of threatened premature labor, is a highly selective beta-2 agonist with the major metabolites of sulfate and glucuronide conjugates. This study investigated the continuous evaluation of the concentration of ritodrine conjugates in relation to the clinical course in twin pregnancy. The subjects were 9 twin-pregnancy mothers who delivered after receiving ritodrine treatment between April 2012 and December 2013. Serum ritodrine sulfate and glucuronide conjugates were deconjugated using their specific enzymes. Ritodrine concentration was measured by liquid chromatography-tandem mass spectrometry. The continuous infusion rate of ritodrine was 2.66±0.67 (0.8-3.54) µg/min/kg, and the average concentration of unchanged ritodrine was 118.8±33.2 (63.8-194.0) ng/mL. During the study period between week 32 and week 36 of gestation, the average ratio of unchanged ritodrine concentration and sulfate ritodrine conjugate concentration for weeks 32, 33, 34, 35, and 36 were 1.7, 1.9, 1.5, 1.7, and 1.7 not significant (N.S.), respectively. The average ratio of unchanged ritodrine concentration and glucuronide ritodrine conjugate concentration were 1.8, 2.2, 1.9, 1.8, and 2.1 (N.S.), respectively. No statistical difference was identified in the ratios of unchanged ritodrine concentration and sulfate or glucuronide ritodrine conjugate concentrations. Large individual differences were shown in the concentration of sulfate and glucuronide during the gestational period. No change in the ratio of the formation of ritodrine metabolites was identified as the gestational age progressed.


Asunto(s)
Glucurónidos/sangre , Embarazo Gemelar/sangre , Ritodrina/farmacocinética , Sulfatos/sangre , Agonistas de Receptores Adrenérgicos beta 2 , Adulto , Femenino , Humanos , Trabajo de Parto Prematuro/sangre , Trabajo de Parto Prematuro/prevención & control , Embarazo , Ritodrina/sangre , Ritodrina/uso terapéutico
2.
Congenit Anom (Kyoto) ; 57(2): 61-63, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-27644460

RESUMEN

Lissencephaly is one of the central nervous system anomalies of Miller-Dieker Syndrome (MDS). Fetuses with lissencephaly have an abnormal smooth brain with fewer folds and grooves that will be detected by ultrasounds or fetal magnetic resonance imaging (MRI) after 30 weeks of gestation. We report a fetus with lissencephaly diagnosed as Miller-Dieker Syndrome postnatally. G banded chromosome analysis revealed 45,X,psu dic(17;Y)(p13;p11.32).ish dic (17;Y)(LIS1-,RARA+, SRY+, DYZ3+) by G-banding analysis using high resolution banding technique. Fetal delayed cortical development will be the findings to perform further investigations including fluorescence in situ hybridization analysis for MDS, a 17p13.3 microdeletion syndrome, pre/postnatally. This will be the first case of MDS with unbalanced translocation between deleted short arm of chromosome 17 and Y chromosome.


Asunto(s)
Bandeo Cromosómico/métodos , Cromosomas Humanos Par 17/genética , Cromosomas Humanos X/genética , Lisencefalias Clásicas y Heterotopias Subcorticales en Banda/diagnóstico , Enfermedades Fetales/diagnóstico , Hibridación Fluorescente in Situ/métodos , Translocación Genética/genética , Adulto , Lisencefalias Clásicas y Heterotopias Subcorticales en Banda/genética , Femenino , Enfermedades Fetales/genética , Humanos , Recién Nacido , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA